Oncolytic Virus Cancer Therapy Market Set for Rapid Growth Through 2036
Author : John snow | Published On : 24 Sep 2026
The oncolytic virus cancer therapy market is expected to expand rapidly during 2026–2036, supported by increasing investments in next-generation cancer treatments, advances in viral engineering, and growing clinical development across multiple tumor types. Oncolytic viruses are designed to selectively infect and destroy cancer cells while stimulating broader antitumor immune responses, creating opportunities for innovative approaches in oncology.
DelveInsight’s Oncolytic Virus Cancer Therapy Market Size, Target Population, Competitive Landscape & Market Forecast provides an assessment of the market across the 7MM, comprising the United States, EU4, the United Kingdom, and Japan. The analysis covers historical and forecasted market trends from 2022 to 2036, along with patient populations, emerging therapies, competitive dynamics, and market opportunities.
To know more about oncolytic virus therapies developers companies, visit @ Oncolytic Virus Landscape - https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Oncolytic Virus Cancer Therapy Market Overview and Growth Outlook
The oncolytic virus cancer therapy market was valued at approximately USD 177 million in the 7MM in 2025. The United States represented the largest share of the market during the same year compared with the EU4, the United Kingdom, and Japan.
The market encompasses a broad range of cancer indications, including melanoma, biliary tract cancer, head and neck cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, breast cancer, prostate cancer, brain cancer, bladder cancer, ovarian cancer, and other malignancies.
Oncolytic virus therapies are particularly being investigated for patients with relapsed or refractory disease. Their ability to combine direct tumor-cell destruction with immune stimulation has generated considerable interest among researchers and developers seeking new treatment approaches for advanced cancers.
Rising Adoption of Novel Cancer Immunotherapies
The increasing adoption of immuno-oncology strategies is one of the major factors supporting the growth of the oncolytic virus cancer therapy market. Unlike conventional treatments that primarily target cancer cells through specific cytotoxic mechanisms, oncolytic viruses can potentially create a localized immune response within tumors.
These therapies may selectively infect malignant cells and cause tumor-cell destruction while releasing tumor-associated antigens that can stimulate immune activity. Certain engineered viruses are additionally designed to deliver therapeutic genes or modify the tumor microenvironment, potentially improving immune recognition and treatment effectiveness.
The expanding focus on personalized and targeted cancer treatments is therefore contributing to increased research into oncolytic virus-based therapeutic platforms.
Advances in Viral Engineering and Clinical Development
Technological progress in genetic engineering has enabled researchers to modify viral platforms to improve tumor selectivity, immune activation, and therapeutic payload delivery. Current clinical development includes adenoviruses, herpes simplex viruses, vaccinia viruses, reoviruses, measles viruses, Newcastle disease viruses, picornaviruses, Maraba viruses, vesicular stomatitis viruses, and other platforms.
The clinical pipeline includes candidates such as Cretostimogene grenadenorepvec, CAN-2409, AdAPT-001, LOAd703, RP1, RP2, VG 161, BS001, Olvi-Vec, CF33, BT-001, TG6050, and Pelareorep.
Increasing clinical trial activity across melanoma, bladder cancer, glioblastoma, ovarian cancer, pancreatic cancer, biliary tract cancer, and other solid tumors is expected to strengthen the commercial potential of this therapeutic class.
Discover real-time oncolytic virus analysis @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Competitive Landscape of Oncolytic Virus Cancer Therapy
The competitive landscape is characterized by multiple biotechnology and pharmaceutical companies advancing investigational therapies across different cancer indications. Key developers include CG Oncology, Candel Therapeutics, EpicentRx, Lokon Pharma, Replimune, Virogin Biotech, Binhui Bio, Genelux, Imugene, BioInvent, Transgene, and Oncolytics Biotech, among others.
Genelux’s Olvi-Vec is a genetically modified vaccinia virus being investigated across several cancer types. Its development strategy focuses on direct tumor-cell destruction, activation of tumor-specific immune responses, and modification of the tumor microenvironment.
CG Oncology’s cretostimogene grenadenorepvec is an investigational intravesical oncolytic immunotherapy being studied in non-muscle-invasive bladder cancer. The candidate has been evaluated in Phase III programs targeting different patient populations with bladder cancer.
Another example is BT-001, developed through collaboration between BioInvent and Transgene. The engineered oncolytic virus is designed to deliver an anti-CTLA-4 antibody directly within tumors and is being investigated in combination with pembrolizumab.
Recent Developments Shaping the Market
The oncolytic virus cancer therapy landscape has witnessed several notable developments in 2026. In August 2026, Replimune announced that the U.S. FDA granted accelerated approval to TUDRIQEVTM (vusolimogene oderparepvec-wtpg), formerly RP1, in combination with nivolumab for certain adults with unresectable advanced cutaneous melanoma following progression after an anti-PD-1-based regimen.
In July 2026, UroGen Pharma announced FDA clearance of its IND application for UGN-501, supporting plans for a Phase I clinical trial in non-muscle-invasive bladder cancer.
Candel Therapeutics initiated the global pivotal Phase III AURORA trial in June 2026 to evaluate CAN-2409 with valacyclovir and continued pembrolizumab treatment in patients with metastatic non-squamous NSCLC following disease progression.
Meanwhile, CG Oncology reported encouraging Phase II results for cretostimogene grenadenorepvec plus gemcitabine in high-risk NMIBC in May 2026. Genelux also reported continued clinical progress for Olvi-Vec, with Phase III ovarian cancer topline data anticipated during the second half of 2026.
Oncolytic Virus Cancer Therapy Patient Pool and Market Opportunity
The addressable patient population represents another important component of the market opportunity. DelveInsight evaluates total cases of selected cancer types, the target patient pool for oncolytic virus therapies, and treated cases across major indications.
The analysis covers melanoma, biliary tract cancer, head and neck cancer, pancreatic cancer, NSCLC, hepatocellular carcinoma, breast cancer, prostate cancer, brain cancer, bladder cancer, ovarian cancer, and other selected cancers.
The report evaluates the epidemiological landscape across the 7MM for the 2022–2036 study period. The growing burden of advanced and treatment-resistant cancers, combined with limitations associated with existing treatment approaches, may create opportunities for novel oncolytic virus therapies.
Future Outlook for Oncolytic Virus Cancer Therapy
The future development of the oncolytic virus cancer therapy market will depend on clinical efficacy, safety, regulatory progress, manufacturing capabilities, patient selection, and the ability of developers to demonstrate meaningful benefits in increasingly competitive oncology treatment landscapes.
As clinical programs mature, emerging therapies could expand the application of oncolytic viruses across multiple solid tumors. Combination strategies with immune checkpoint inhibitors, chemotherapy, targeted therapies, and other immunotherapies may further influence the treatment landscape.
Scope of the Oncolytic Virus Cancer Therapy Market Report
DelveInsight’s report provides comprehensive coverage of the oncolytic virus cancer therapy landscape, including patient population forecasts, therapeutics market size, pipeline analysis, market size and trends, market opportunities, unmet needs, KOL perspectives, market access, and reimbursement.
The report covers the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. It also evaluates key emerging therapies and their potential impact on future market dynamics.
The assessment can support stakeholders in understanding evolving treatment patterns, competitive developments, patient opportunities, and the broader commercial landscape surrounding oncolytic virus-based cancer therapies.
Learn more about the hydroxychloroquine oncolytic virus cancer therapy @ Oncolytic Virus Analytics - https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Conclusion
The oncolytic virus cancer therapy market is entering an important phase of development, supported by advances in genetic engineering, expanding clinical pipelines, increasing interest in immuno-oncology, and a substantial population of patients with advanced or treatment-resistant cancers. Approved therapies such as IMLYGIC and DELYTACT have established clinical precedents, while newer candidates continue to expand across bladder cancer, melanoma, ovarian cancer, pancreatic cancer, NSCLC, and other malignancies. Continued clinical validation, regulatory progress, strategic collaborations, and combination-treatment research are expected to influence the market through 2036. As developers advance innovative viral platforms, oncolytic virus therapies may become an increasingly important component of the evolving cancer treatment landscape.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Abhishek kumar
